nodes	percent_of_prediction	percent_of_DWPC	metapath
Niflumic Acid—PLA2G4A—amyotrophic lateral sclerosis	0.732	0.828	CbGaD
Niflumic Acid—PTGS2—amyotrophic lateral sclerosis	0.153	0.173	CbGaD
Niflumic Acid—CLCNKA—cerebellum—amyotrophic lateral sclerosis	0.00274	0.109	CbGeAlD
Niflumic Acid—PTGS2—hindlimb—amyotrophic lateral sclerosis	0.00193	0.0771	CbGeAlD
Niflumic Acid—PTGS2—appendage—amyotrophic lateral sclerosis	0.00166	0.0662	CbGeAlD
Niflumic Acid—SLC16A7—medulla oblongata—amyotrophic lateral sclerosis	0.00129	0.0514	CbGeAlD
Niflumic Acid—PLA2G1B—nervous system—amyotrophic lateral sclerosis	0.00115	0.0459	CbGeAlD
Niflumic Acid—Floctafenine—PTGS2—amyotrophic lateral sclerosis	0.00114	0.719	CrCbGaD
Niflumic Acid—PLA2G1B—central nervous system—amyotrophic lateral sclerosis	0.00111	0.0442	CbGeAlD
Niflumic Acid—SLC16A7—nervous system—amyotrophic lateral sclerosis	0.000968	0.0387	CbGeAlD
Niflumic Acid—SLC16A7—central nervous system—amyotrophic lateral sclerosis	0.000932	0.0372	CbGeAlD
Niflumic Acid—PLA2G4A—medulla oblongata—amyotrophic lateral sclerosis	0.000932	0.0372	CbGeAlD
Niflumic Acid—SLC16A7—cerebellum—amyotrophic lateral sclerosis	0.000911	0.0364	CbGeAlD
Niflumic Acid—PLA2G1B—brain—amyotrophic lateral sclerosis	0.000879	0.0351	CbGeAlD
Niflumic Acid—PLA2G4A—spinal cord—amyotrophic lateral sclerosis	0.000831	0.0332	CbGeAlD
Niflumic Acid—SLC16A1—medulla oblongata—amyotrophic lateral sclerosis	0.00082	0.0327	CbGeAlD
Niflumic Acid—SLC16A7—brain—amyotrophic lateral sclerosis	0.00074	0.0295	CbGeAlD
Niflumic Acid—SLC16A1—spinal cord—amyotrophic lateral sclerosis	0.000732	0.0292	CbGeAlD
Niflumic Acid—PLA2G4A—nervous system—amyotrophic lateral sclerosis	0.0007	0.0279	CbGeAlD
Niflumic Acid—PLA2G4A—central nervous system—amyotrophic lateral sclerosis	0.000674	0.0269	CbGeAlD
Niflumic Acid—SLC16A1—nervous system—amyotrophic lateral sclerosis	0.000616	0.0246	CbGeAlD
Niflumic Acid—SLC16A1—central nervous system—amyotrophic lateral sclerosis	0.000594	0.0237	CbGeAlD
Niflumic Acid—SLC16A1—cerebellum—amyotrophic lateral sclerosis	0.00058	0.0232	CbGeAlD
Niflumic Acid—PTGS2—embryo—amyotrophic lateral sclerosis	0.00055	0.022	CbGeAlD
Niflumic Acid—PLA2G4A—brain—amyotrophic lateral sclerosis	0.000535	0.0214	CbGeAlD
Niflumic Acid—SLC16A1—brain—amyotrophic lateral sclerosis	0.000471	0.0188	CbGeAlD
Niflumic Acid—Mefenamic acid—PTGS2—amyotrophic lateral sclerosis	0.000444	0.281	CrCbGaD
Niflumic Acid—PLA2G4A—Integrated Pancreatic Cancer Pathway—CASP12—amyotrophic lateral sclerosis	0.000441	0.00499	CbGpPWpGaD
Niflumic Acid—PTGS1—Selenium Micronutrient Network—GSR—amyotrophic lateral sclerosis	0.000435	0.00491	CbGpPWpGaD
Niflumic Acid—PTGS1—Synthesis of Prostaglandins (PG) and Thromboxanes (TX)—PTGS2—amyotrophic lateral sclerosis	0.000433	0.00489	CbGpPWpGaD
Niflumic Acid—PTGS1—Prostaglandin Synthesis and Regulation—PLA2G4A—amyotrophic lateral sclerosis	0.000417	0.00471	CbGpPWpGaD
Niflumic Acid—PLA2G4A—AGE/RAGE pathway—CASP9—amyotrophic lateral sclerosis	0.000408	0.00461	CbGpPWpGaD
Niflumic Acid—PLA2G1B—Phospholipid metabolism—PLA2G4A—amyotrophic lateral sclerosis	0.0004	0.00452	CbGpPWpGaD
Niflumic Acid—SLC16A7—Transmembrane transport of small molecules—SLC1A2—amyotrophic lateral sclerosis	0.0004	0.00452	CbGpPWpGaD
Niflumic Acid—PTGS2—Signaling mediated by p38-alpha and p38-beta—ATF1—amyotrophic lateral sclerosis	0.000382	0.00431	CbGpPWpGaD
Niflumic Acid—PLA2G4A—Phospholipid metabolism—CHAT—amyotrophic lateral sclerosis	0.000369	0.00417	CbGpPWpGaD
Niflumic Acid—PLA2G4A—AGE/RAGE pathway—SOD1—amyotrophic lateral sclerosis	0.000366	0.00414	CbGpPWpGaD
Niflumic Acid—PLA2G4A—Integrated Pancreatic Cancer Pathway—RARA—amyotrophic lateral sclerosis	0.00036	0.00406	CbGpPWpGaD
Niflumic Acid—UGT1A9—NRF2 pathway—GSR—amyotrophic lateral sclerosis	0.000356	0.00402	CbGpPWpGaD
Niflumic Acid—PTGS2—medulla oblongata—amyotrophic lateral sclerosis	0.000352	0.014	CbGeAlD
Niflumic Acid—PLA2G4A—Prostaglandin Synthesis and Regulation—PTGS2—amyotrophic lateral sclerosis	0.000348	0.00393	CbGpPWpGaD
Niflumic Acid—PTGS2—Selenium Micronutrient Network—GSR—amyotrophic lateral sclerosis	0.000345	0.0039	CbGpPWpGaD
Niflumic Acid—PLA2G1B—Metabolism of lipids and lipoproteins—PLB1—amyotrophic lateral sclerosis	0.000344	0.00389	CbGpPWpGaD
Niflumic Acid—PTGS2—Calcium signaling in the CD4+ TCR pathway—CD40LG—amyotrophic lateral sclerosis	0.00034	0.00384	CbGpPWpGaD
Niflumic Acid—SLC16A7—Transmembrane transport of small molecules—AQP4—amyotrophic lateral sclerosis	0.00034	0.00384	CbGpPWpGaD
Niflumic Acid—SLC16A7—Transmembrane transport of small molecules—SLC1A3—amyotrophic lateral sclerosis	0.00034	0.00384	CbGpPWpGaD
Niflumic Acid—PTGS1—Overview of nanoparticle effects—PTGS2—amyotrophic lateral sclerosis	0.000339	0.00383	CbGpPWpGaD
Niflumic Acid—SLC16A1—SLC-mediated transmembrane transport—SLC1A2—amyotrophic lateral sclerosis	0.000336	0.0038	CbGpPWpGaD
Niflumic Acid—PTGS2—Prostaglandin Synthesis and Regulation—PLA2G4A—amyotrophic lateral sclerosis	0.000331	0.00374	CbGpPWpGaD
Niflumic Acid—PTGS1—spinal cord—amyotrophic lateral sclerosis	0.000328	0.0131	CbGeAlD
Niflumic Acid—PLA2G4A—Platelet activation, signaling and aggregation—TUBA4A—amyotrophic lateral sclerosis	0.00032	0.00362	CbGpPWpGaD
Niflumic Acid—PTGS2—spinal cord—amyotrophic lateral sclerosis	0.000314	0.0125	CbGeAlD
Niflumic Acid—UGT1A9—Metapathway biotransformation—GSR—amyotrophic lateral sclerosis	0.000308	0.00348	CbGpPWpGaD
Niflumic Acid—PLA2G4A—Signaling mediated by p38-alpha and p38-beta—PTGS2—amyotrophic lateral sclerosis	0.000308	0.00348	CbGpPWpGaD
Niflumic Acid—SLC16A1—Hemostasis—KIFAP3—amyotrophic lateral sclerosis	0.000306	0.00346	CbGpPWpGaD
Niflumic Acid—SLC16A7—Transmembrane transport of small molecules—SLC6A1—amyotrophic lateral sclerosis	0.000303	0.00342	CbGpPWpGaD
Niflumic Acid—PTGS2—Signaling mediated by p38-alpha and p38-beta—PLA2G4A—amyotrophic lateral sclerosis	0.000293	0.00331	CbGpPWpGaD
Niflumic Acid—PLA2G4A—Platelet activation, signaling and aggregation—PFN1—amyotrophic lateral sclerosis	0.000288	0.00326	CbGpPWpGaD
Niflumic Acid—PLA2G4A—Metabolism of lipids and lipoproteins—VAPB—amyotrophic lateral sclerosis	0.000286	0.00323	CbGpPWpGaD
Niflumic Acid—SLC16A1—SLC-mediated transmembrane transport—SLC1A3—amyotrophic lateral sclerosis	0.000286	0.00323	CbGpPWpGaD
Niflumic Acid—PTGS1—Eicosanoid Synthesis—PTGS2—amyotrophic lateral sclerosis	0.000281	0.00318	CbGpPWpGaD
Niflumic Acid—PLA2G1B—Metabolism—TPK1—amyotrophic lateral sclerosis	0.00028	0.00316	CbGpPWpGaD
Niflumic Acid—PLA2G1B—Metabolism—VAPB—amyotrophic lateral sclerosis	0.00028	0.00316	CbGpPWpGaD
Niflumic Acid—PTGS2—Spinal Cord Injury—RTN4—amyotrophic lateral sclerosis	0.000278	0.00314	CbGpPWpGaD
Niflumic Acid—PTGS1—Arachidonic acid metabolism—PLA2G4A—amyotrophic lateral sclerosis	0.000277	0.00313	CbGpPWpGaD
Niflumic Acid—PTGS1—nervous system—amyotrophic lateral sclerosis	0.000277	0.011	CbGeAlD
Niflumic Acid—PTGS1—central nervous system—amyotrophic lateral sclerosis	0.000266	0.0106	CbGeAlD
Niflumic Acid—SLC16A1—Transmembrane transport of small molecules—TRPM7—amyotrophic lateral sclerosis	0.000265	0.00299	CbGpPWpGaD
Niflumic Acid—PTGS2—nervous system—amyotrophic lateral sclerosis	0.000264	0.0105	CbGeAlD
Niflumic Acid—PLA2G4A—Metabolism of lipids and lipoproteins—VAPA—amyotrophic lateral sclerosis	0.000262	0.00295	CbGpPWpGaD
Niflumic Acid—PLA2G1B—Metabolism of lipids and lipoproteins—CHAT—amyotrophic lateral sclerosis	0.000261	0.00295	CbGpPWpGaD
Niflumic Acid—UGT1A9—NRF2 pathway—SLC6A1—amyotrophic lateral sclerosis	0.00026	0.00294	CbGpPWpGaD
Niflumic Acid—PLA2G1B—Metabolism—VAPA—amyotrophic lateral sclerosis	0.000256	0.00289	CbGpPWpGaD
Niflumic Acid—SLC16A1—SLC-mediated transmembrane transport—SLC6A1—amyotrophic lateral sclerosis	0.000255	0.00288	CbGpPWpGaD
Niflumic Acid—PTGS2—central nervous system—amyotrophic lateral sclerosis	0.000254	0.0102	CbGeAlD
Niflumic Acid—PTGS2—cerebellum—amyotrophic lateral sclerosis	0.000249	0.00993	CbGeAlD
Niflumic Acid—PLA2G4A—Integrated Pancreatic Cancer Pathway—MAPT—amyotrophic lateral sclerosis	0.000247	0.00279	CbGpPWpGaD
Niflumic Acid—PLA2G4A—Metabolism of lipids and lipoproteins—SACM1L—amyotrophic lateral sclerosis	0.000243	0.00275	CbGpPWpGaD
Niflumic Acid—PTGS2—Quercetin and Nf-kB/ AP-1 Induced Cell Apoptosis—VEGFA—amyotrophic lateral sclerosis	0.000243	0.00275	CbGpPWpGaD
Niflumic Acid—PLA2G4A—Integrated Pancreatic Cancer Pathway—CST3—amyotrophic lateral sclerosis	0.00024	0.00271	CbGpPWpGaD
Niflumic Acid—PLA2G4A—Hemostasis—KIFAP3—amyotrophic lateral sclerosis	0.000238	0.00269	CbGpPWpGaD
Niflumic Acid—PLA2G1B—Metabolism—SACM1L—amyotrophic lateral sclerosis	0.000238	0.00269	CbGpPWpGaD
Niflumic Acid—UGT1A9—Metabolism of lipids and lipoproteins—VAPB—amyotrophic lateral sclerosis	0.000237	0.00268	CbGpPWpGaD
Niflumic Acid—PTGS2—Integrated Pancreatic Cancer Pathway—CASP12—amyotrophic lateral sclerosis	0.000237	0.00267	CbGpPWpGaD
Niflumic Acid—UGT1A9—Phase II conjugation—GSTP1—amyotrophic lateral sclerosis	0.000235	0.00266	CbGpPWpGaD
Niflumic Acid—PTGS1—Prostaglandin Synthesis and Regulation—PTGS2—amyotrophic lateral sclerosis	0.000235	0.00266	CbGpPWpGaD
Niflumic Acid—PLA2G4A—Arachidonic acid metabolism—PTGS2—amyotrophic lateral sclerosis	0.000231	0.00261	CbGpPWpGaD
Niflumic Acid—PLA2G4A—Metabolism of lipids and lipoproteins—FIG4—amyotrophic lateral sclerosis	0.000229	0.00258	CbGpPWpGaD
Niflumic Acid—PTGS2—Spinal Cord Injury—GFAP—amyotrophic lateral sclerosis	0.000227	0.00256	CbGpPWpGaD
Niflumic Acid—PLA2G4A—Integrated Pancreatic Cancer Pathway—IGFBP3—amyotrophic lateral sclerosis	0.000226	0.00255	CbGpPWpGaD
Niflumic Acid—PTGS2—Spinal Cord Injury—AQP4—amyotrophic lateral sclerosis	0.000224	0.00253	CbGpPWpGaD
Niflumic Acid—PLA2G1B—Metabolism—FIG4—amyotrophic lateral sclerosis	0.000224	0.00253	CbGpPWpGaD
Niflumic Acid—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—CD40LG—amyotrophic lateral sclerosis	0.00022	0.00249	CbGpPWpGaD
Niflumic Acid—PTGS2—Arachidonic acid metabolism—PLA2G4A—amyotrophic lateral sclerosis	0.00022	0.00249	CbGpPWpGaD
Niflumic Acid—UGT1A9—Metabolism of lipids and lipoproteins—VAPA—amyotrophic lateral sclerosis	0.000217	0.00245	CbGpPWpGaD
Niflumic Acid—SLC16A1—Hemostasis—TUBA4A—amyotrophic lateral sclerosis	0.000212	0.0024	CbGpPWpGaD
Niflumic Acid—PTGS2—S1P1 pathway—VEGFA—amyotrophic lateral sclerosis	0.000212	0.00239	CbGpPWpGaD
Niflumic Acid—PTGS1—brain—amyotrophic lateral sclerosis	0.000211	0.00844	CbGeAlD
Niflumic Acid—PLA2G1B—Metabolism—DAO—amyotrophic lateral sclerosis	0.000202	0.00229	CbGpPWpGaD
Niflumic Acid—PTGS2—brain—amyotrophic lateral sclerosis	0.000202	0.00806	CbGeAlD
Niflumic Acid—UGT1A9—Metabolism of lipids and lipoproteins—SACM1L—amyotrophic lateral sclerosis	0.000201	0.00228	CbGpPWpGaD
Niflumic Acid—UGT1A9—NRF2 pathway—SQSTM1—amyotrophic lateral sclerosis	0.000201	0.00227	CbGpPWpGaD
Niflumic Acid—SLC16A1—Hemostasis—RAB5A—amyotrophic lateral sclerosis	0.000197	0.00223	CbGpPWpGaD
Niflumic Acid—PTGS1—Selenium Micronutrient Network—SOD1—amyotrophic lateral sclerosis	0.000197	0.00222	CbGpPWpGaD
Niflumic Acid—PTGS1—Metabolism of lipids and lipoproteins—VAPB—amyotrophic lateral sclerosis	0.000193	0.00218	CbGpPWpGaD
Niflumic Acid—PTGS2—Integrated Pancreatic Cancer Pathway—RARA—amyotrophic lateral sclerosis	0.000193	0.00218	CbGpPWpGaD
Niflumic Acid—SLC16A1—Hemostasis—PFN1—amyotrophic lateral sclerosis	0.000191	0.00216	CbGpPWpGaD
Niflumic Acid—UGT1A9—Metabolism of lipids and lipoproteins—FIG4—amyotrophic lateral sclerosis	0.000189	0.00214	CbGpPWpGaD
Niflumic Acid—PLA2G4A—Signaling mediated by p38-alpha and p38-beta—TP53—amyotrophic lateral sclerosis	0.000183	0.00207	CbGpPWpGaD
Niflumic Acid—PTGS1—Metabolism of lipids and lipoproteins—VAPA—amyotrophic lateral sclerosis	0.000177	0.002	CbGpPWpGaD
Niflumic Acid—PLA2G4A—Integrated Pancreatic Cancer Pathway—CASP9—amyotrophic lateral sclerosis	0.000175	0.00197	CbGpPWpGaD
Niflumic Acid—PLA2G4A—AGE/RAGE pathway—CASP3—amyotrophic lateral sclerosis	0.000172	0.00194	CbGpPWpGaD
Niflumic Acid—SLC16A1—Transmembrane transport of small molecules—SLC1A2—amyotrophic lateral sclerosis	0.000171	0.00193	CbGpPWpGaD
Niflumic Acid—PLA2G4A—Hemostasis—TUBA4A—amyotrophic lateral sclerosis	0.000165	0.00186	CbGpPWpGaD
Niflumic Acid—PTGS1—Metabolism of lipids and lipoproteins—SACM1L—amyotrophic lateral sclerosis	0.000164	0.00186	CbGpPWpGaD
Niflumic Acid—SLC16A1—Metabolism—VAPB—amyotrophic lateral sclerosis	0.000164	0.00185	CbGpPWpGaD
Niflumic Acid—SLC16A1—Metabolism—TPK1—amyotrophic lateral sclerosis	0.000164	0.00185	CbGpPWpGaD
Niflumic Acid—PLA2G4A—AGE/RAGE pathway—MMP9—amyotrophic lateral sclerosis	0.000163	0.00184	CbGpPWpGaD
Niflumic Acid—UGT1A9—NRF2 pathway—GSTP1—amyotrophic lateral sclerosis	0.000157	0.00177	CbGpPWpGaD
Niflumic Acid—PLA2G4A—Metabolism of lipids and lipoproteins—PLB1—amyotrophic lateral sclerosis	0.000157	0.00177	CbGpPWpGaD
Niflumic Acid—PTGS1—Arachidonic acid metabolism—PTGS2—amyotrophic lateral sclerosis	0.000156	0.00177	CbGpPWpGaD
Niflumic Acid—PTGS2—Selenium Micronutrient Network—SOD1—amyotrophic lateral sclerosis	0.000156	0.00176	CbGpPWpGaD
Niflumic Acid—PTGS1—Metabolism of lipids and lipoproteins—FIG4—amyotrophic lateral sclerosis	0.000154	0.00174	CbGpPWpGaD
Niflumic Acid—PLA2G4A—Hemostasis—RAB5A—amyotrophic lateral sclerosis	0.000153	0.00173	CbGpPWpGaD
Niflumic Acid—PLA2G1B—Metabolism—PLB1—amyotrophic lateral sclerosis	0.000153	0.00173	CbGpPWpGaD
Niflumic Acid—PTGS2—Metabolism of lipids and lipoproteins—VAPB—amyotrophic lateral sclerosis	0.000153	0.00173	CbGpPWpGaD
Niflumic Acid—SLC16A1—Metabolism—VAPA—amyotrophic lateral sclerosis	0.00015	0.00169	CbGpPWpGaD
Niflumic Acid—PLA2G4A—Hemostasis—PFN1—amyotrophic lateral sclerosis	0.000149	0.00168	CbGpPWpGaD
Niflumic Acid—PLA2G4A—Integrated Pancreatic Cancer Pathway—BDNF—amyotrophic lateral sclerosis	0.000147	0.00166	CbGpPWpGaD
Niflumic Acid—SLC16A1—Transmembrane transport of small molecules—SLC1A3—amyotrophic lateral sclerosis	0.000145	0.00164	CbGpPWpGaD
Niflumic Acid—SLC16A1—Transmembrane transport of small molecules—AQP4—amyotrophic lateral sclerosis	0.000145	0.00164	CbGpPWpGaD
Niflumic Acid—PLA2G1B—Metabolism—GSR—amyotrophic lateral sclerosis	0.000142	0.0016	CbGpPWpGaD
Niflumic Acid—PTGS2—Metabolism of lipids and lipoproteins—VAPA—amyotrophic lateral sclerosis	0.00014	0.00158	CbGpPWpGaD
Niflumic Acid—PLA2G4A—Platelet activation, signaling and aggregation—SOD1—amyotrophic lateral sclerosis	0.000139	0.00157	CbGpPWpGaD
Niflumic Acid—SLC16A1—Metabolism—SACM1L—amyotrophic lateral sclerosis	0.000139	0.00157	CbGpPWpGaD
Niflumic Acid—UGT1A9—Biological oxidations—GSTP1—amyotrophic lateral sclerosis	0.000138	0.00156	CbGpPWpGaD
Niflumic Acid—UGT1A9—Metapathway biotransformation—GSTP1—amyotrophic lateral sclerosis	0.000136	0.00153	CbGpPWpGaD
Niflumic Acid—PTGS2—Integrated Pancreatic Cancer Pathway—MAPT—amyotrophic lateral sclerosis	0.000133	0.0015	CbGpPWpGaD
Niflumic Acid—SLC16A1—Metabolism—FIG4—amyotrophic lateral sclerosis	0.000131	0.00148	CbGpPWpGaD
Niflumic Acid—PTGS2—Metabolism of lipids and lipoproteins—SACM1L—amyotrophic lateral sclerosis	0.00013	0.00147	CbGpPWpGaD
Niflumic Acid—UGT1A9—Metabolism of lipids and lipoproteins—PLB1—amyotrophic lateral sclerosis	0.00013	0.00147	CbGpPWpGaD
Niflumic Acid—SLC16A1—Transmembrane transport of small molecules—SLC6A1—amyotrophic lateral sclerosis	0.000129	0.00146	CbGpPWpGaD
Niflumic Acid—PLA2G1B—Metabolism of lipids and lipoproteins—PLA2G4A—amyotrophic lateral sclerosis	0.000129	0.00146	CbGpPWpGaD
Niflumic Acid—PTGS2—Integrated Pancreatic Cancer Pathway—CST3—amyotrophic lateral sclerosis	0.000129	0.00145	CbGpPWpGaD
Niflumic Acid—PLA2G4A—Metabolism—TPK1—amyotrophic lateral sclerosis	0.000127	0.00144	CbGpPWpGaD
Niflumic Acid—PLA2G4A—Metabolism—VAPB—amyotrophic lateral sclerosis	0.000127	0.00144	CbGpPWpGaD
Niflumic Acid—PTGS2—Metabolism of lipids and lipoproteins—FIG4—amyotrophic lateral sclerosis	0.000123	0.00138	CbGpPWpGaD
Niflumic Acid—PTGS2—Integrated Pancreatic Cancer Pathway—IGFBP3—amyotrophic lateral sclerosis	0.000121	0.00137	CbGpPWpGaD
Niflumic Acid—PLA2G4A—Metabolism of lipids and lipoproteins—CHAT—amyotrophic lateral sclerosis	0.000119	0.00134	CbGpPWpGaD
Niflumic Acid—SLC16A1—Metabolism—DAO—amyotrophic lateral sclerosis	0.000118	0.00134	CbGpPWpGaD
Niflumic Acid—PLA2G4A—Metabolism—VAPA—amyotrophic lateral sclerosis	0.000116	0.00132	CbGpPWpGaD
Niflumic Acid—PLA2G1B—Metabolism—CHAT—amyotrophic lateral sclerosis	0.000116	0.00131	CbGpPWpGaD
Niflumic Acid—PTGS2—Spinal Cord Injury—BDNF—amyotrophic lateral sclerosis	0.000116	0.00131	CbGpPWpGaD
Niflumic Acid—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—CASP3—amyotrophic lateral sclerosis	0.000115	0.0013	CbGpPWpGaD
Niflumic Acid—PTGS1—Biological oxidations—GSTP1—amyotrophic lateral sclerosis	0.000112	0.00127	CbGpPWpGaD
Niflumic Acid—PLA2G4A—Metabolism—SACM1L—amyotrophic lateral sclerosis	0.000108	0.00122	CbGpPWpGaD
Niflumic Acid—PLA2G1B—Metabolism of lipids and lipoproteins—APOE—amyotrophic lateral sclerosis	0.000106	0.0012	CbGpPWpGaD
Niflumic Acid—PTGS1—Metabolism of lipids and lipoproteins—PLB1—amyotrophic lateral sclerosis	0.000106	0.0012	CbGpPWpGaD
Niflumic Acid—UGT1A9—Metabolism—TPK1—amyotrophic lateral sclerosis	0.000106	0.00119	CbGpPWpGaD
Niflumic Acid—UGT1A9—Metabolism—VAPB—amyotrophic lateral sclerosis	0.000106	0.00119	CbGpPWpGaD
Niflumic Acid—PTGS2—Aryl Hydrocarbon Receptor—VEGFA—amyotrophic lateral sclerosis	0.000104	0.00118	CbGpPWpGaD
Niflumic Acid—PLA2G4A—Metabolism—FIG4—amyotrophic lateral sclerosis	0.000102	0.00115	CbGpPWpGaD
Niflumic Acid—PTGS1—Selenium Micronutrient Network—PTGS2—amyotrophic lateral sclerosis	9.94e-05	0.00112	CbGpPWpGaD
Niflumic Acid—UGT1A9—Metabolism of lipids and lipoproteins—CHAT—amyotrophic lateral sclerosis	9.84e-05	0.00111	CbGpPWpGaD
Niflumic Acid—PTGS2—Signaling mediated by p38-alpha and p38-beta—TP53—amyotrophic lateral sclerosis	9.82e-05	0.00111	CbGpPWpGaD
Niflumic Acid—UGT1A9—Metabolism—VAPA—amyotrophic lateral sclerosis	9.65e-05	0.00109	CbGpPWpGaD
Niflumic Acid—PLA2G4A—Integrated Pancreatic Cancer Pathway—IGF1—amyotrophic lateral sclerosis	9.55e-05	0.00108	CbGpPWpGaD
Niflumic Acid—PTGS2—Integrated Pancreatic Cancer Pathway—CASP9—amyotrophic lateral sclerosis	9.36e-05	0.00106	CbGpPWpGaD
Niflumic Acid—SLC16A1—Hemostasis—SOD1—amyotrophic lateral sclerosis	9.24e-05	0.00104	CbGpPWpGaD
Niflumic Acid—PLA2G4A—Metabolism—DAO—amyotrophic lateral sclerosis	9.21e-05	0.00104	CbGpPWpGaD
Niflumic Acid—UGT1A9—Metabolism—SACM1L—amyotrophic lateral sclerosis	8.97e-05	0.00101	CbGpPWpGaD
Niflumic Acid—SLC16A1—Metabolism—PLB1—amyotrophic lateral sclerosis	8.97e-05	0.00101	CbGpPWpGaD
Niflumic Acid—PTGS1—Metabolism—TPK1—amyotrophic lateral sclerosis	8.6e-05	0.000972	CbGpPWpGaD
Niflumic Acid—PTGS1—Metabolism—VAPB—amyotrophic lateral sclerosis	8.6e-05	0.000972	CbGpPWpGaD
Niflumic Acid—PLA2G4A—Platelet activation, signaling and aggregation—IGF1—amyotrophic lateral sclerosis	8.5e-05	0.00096	CbGpPWpGaD
Niflumic Acid—UGT1A9—Metabolism—FIG4—amyotrophic lateral sclerosis	8.44e-05	0.000953	CbGpPWpGaD
Niflumic Acid—PTGS2—Metabolism of lipids and lipoproteins—PLB1—amyotrophic lateral sclerosis	8.4e-05	0.000949	CbGpPWpGaD
Niflumic Acid—SLC16A1—Hemostasis—PLA2G4A—amyotrophic lateral sclerosis	8.28e-05	0.000936	CbGpPWpGaD
Niflumic Acid—SLC16A1—Metabolism—GSR—amyotrophic lateral sclerosis	8.28e-05	0.000935	CbGpPWpGaD
Niflumic Acid—PTGS2—Disease—TPK1—amyotrophic lateral sclerosis	8.15e-05	0.000921	CbGpPWpGaD
Niflumic Acid—PTGS1—Metabolism of lipids and lipoproteins—CHAT—amyotrophic lateral sclerosis	8.02e-05	0.000906	CbGpPWpGaD
Niflumic Acid—PLA2G4A—Integrated Pancreatic Cancer Pathway—PTGS2—amyotrophic lateral sclerosis	7.92e-05	0.000894	CbGpPWpGaD
Niflumic Acid—PTGS2—Integrated Pancreatic Cancer Pathway—BDNF—amyotrophic lateral sclerosis	7.89e-05	0.000891	CbGpPWpGaD
Niflumic Acid—PTGS1—Metabolism—VAPA—amyotrophic lateral sclerosis	7.87e-05	0.000889	CbGpPWpGaD
Niflumic Acid—UGT1A9—Metabolism—DAO—amyotrophic lateral sclerosis	7.63e-05	0.000862	CbGpPWpGaD
Niflumic Acid—PTGS2—Integrated Pancreatic Cancer Pathway—PLA2G4A—amyotrophic lateral sclerosis	7.53e-05	0.000851	CbGpPWpGaD
Niflumic Acid—PLA2G4A—Signaling by GPCR—C5AR1—amyotrophic lateral sclerosis	7.49e-05	0.000846	CbGpPWpGaD
Niflumic Acid—PLA2G4A—Integrated Pancreatic Cancer Pathway—CASP3—amyotrophic lateral sclerosis	7.35e-05	0.00083	CbGpPWpGaD
Niflumic Acid—PTGS1—Metabolism—SACM1L—amyotrophic lateral sclerosis	7.31e-05	0.000826	CbGpPWpGaD
Niflumic Acid—PLA2G1B—Metabolism of lipids and lipoproteins—PTGS2—amyotrophic lateral sclerosis	7.27e-05	0.000821	CbGpPWpGaD
Niflumic Acid—PLA2G4A—Hemostasis—SOD1—amyotrophic lateral sclerosis	7.18e-05	0.000811	CbGpPWpGaD
Niflumic Acid—PLA2G4A—Metabolism—PLB1—amyotrophic lateral sclerosis	6.98e-05	0.000788	CbGpPWpGaD
Niflumic Acid—PTGS1—Metabolism—FIG4—amyotrophic lateral sclerosis	6.88e-05	0.000777	CbGpPWpGaD
Niflumic Acid—PTGS2—Metabolism—TPK1—amyotrophic lateral sclerosis	6.83e-05	0.000771	CbGpPWpGaD
Niflumic Acid—PTGS2—Metabolism—VAPB—amyotrophic lateral sclerosis	6.83e-05	0.000771	CbGpPWpGaD
Niflumic Acid—SLC16A1—Metabolism—CHAT—amyotrophic lateral sclerosis	6.8e-05	0.000768	CbGpPWpGaD
Niflumic Acid—PTGS2—Disease—VTA1—amyotrophic lateral sclerosis	6.52e-05	0.000736	CbGpPWpGaD
Niflumic Acid—PLA2G4A—Metabolism—GSR—amyotrophic lateral sclerosis	6.44e-05	0.000727	CbGpPWpGaD
Niflumic Acid—PTGS2—Metabolism of lipids and lipoproteins—CHAT—amyotrophic lateral sclerosis	6.37e-05	0.000719	CbGpPWpGaD
Niflumic Acid—PTGS2—Metabolism—VAPA—amyotrophic lateral sclerosis	6.25e-05	0.000706	CbGpPWpGaD
Niflumic Acid—PLA2G1B—Metabolism—GSTP1—amyotrophic lateral sclerosis	6.25e-05	0.000706	CbGpPWpGaD
Niflumic Acid—PLA2G4A—Integrated Pancreatic Cancer Pathway—VEGFA—amyotrophic lateral sclerosis	6.24e-05	0.000705	CbGpPWpGaD
Niflumic Acid—PTGS1—Metabolism—DAO—amyotrophic lateral sclerosis	6.22e-05	0.000703	CbGpPWpGaD
Niflumic Acid—PLA2G4A—Signaling Pathways—PLB1—amyotrophic lateral sclerosis	5.83e-05	0.000659	CbGpPWpGaD
Niflumic Acid—PTGS2—Metabolism—SACM1L—amyotrophic lateral sclerosis	5.81e-05	0.000656	CbGpPWpGaD
Niflumic Acid—PTGS2—Spinal Cord Injury—CASP3—amyotrophic lateral sclerosis	5.79e-05	0.000655	CbGpPWpGaD
Niflumic Acid—UGT1A9—Metabolism—PLB1—amyotrophic lateral sclerosis	5.78e-05	0.000653	CbGpPWpGaD
Niflumic Acid—PLA2G1B—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	5.74e-05	0.000648	CbGpPWpGaD
Niflumic Acid—SLC16A1—Hemostasis—IGF1—amyotrophic lateral sclerosis	5.63e-05	0.000636	CbGpPWpGaD
Niflumic Acid—PLA2G4A—Platelet activation, signaling and aggregation—VEGFA—amyotrophic lateral sclerosis	5.55e-05	0.000627	CbGpPWpGaD
Niflumic Acid—PLA2G4A—Signaling Pathways—RTN4—amyotrophic lateral sclerosis	5.49e-05	0.00062	CbGpPWpGaD
Niflumic Acid—PTGS2—Spinal Cord Injury—MMP9—amyotrophic lateral sclerosis	5.47e-05	0.000619	CbGpPWpGaD
Niflumic Acid—PTGS2—Metabolism—FIG4—amyotrophic lateral sclerosis	5.46e-05	0.000617	CbGpPWpGaD
Niflumic Acid—UGT1A9—Metabolism—GSR—amyotrophic lateral sclerosis	5.34e-05	0.000603	CbGpPWpGaD
Niflumic Acid—PLA2G4A—Metabolism—CHAT—amyotrophic lateral sclerosis	5.29e-05	0.000597	CbGpPWpGaD
Niflumic Acid—PLA2G4A—Signaling Pathways—VCP—amyotrophic lateral sclerosis	5.2e-05	0.000588	CbGpPWpGaD
Niflumic Acid—PTGS2—Integrated Pancreatic Cancer Pathway—IGF1—amyotrophic lateral sclerosis	5.12e-05	0.000578	CbGpPWpGaD
Niflumic Acid—PLA2G4A—Signaling Pathways—PFN1—amyotrophic lateral sclerosis	5.04e-05	0.000569	CbGpPWpGaD
Niflumic Acid—PTGS2—Disease—CHMP2B—amyotrophic lateral sclerosis	4.94e-05	0.000558	CbGpPWpGaD
Niflumic Acid—PTGS2—Metabolism—DAO—amyotrophic lateral sclerosis	4.94e-05	0.000558	CbGpPWpGaD
Niflumic Acid—UGT1A9—Metabolism of lipids and lipoproteins—PLA2G4A—amyotrophic lateral sclerosis	4.86e-05	0.000549	CbGpPWpGaD
Niflumic Acid—PLA2G4A—Metabolism of lipids and lipoproteins—APOE—amyotrophic lateral sclerosis	4.83e-05	0.000545	CbGpPWpGaD
Niflumic Acid—PLA2G1B—Metabolism—APOE—amyotrophic lateral sclerosis	4.72e-05	0.000533	CbGpPWpGaD
Niflumic Acid—PTGS1—Metabolism—PLB1—amyotrophic lateral sclerosis	4.71e-05	0.000532	CbGpPWpGaD
Niflumic Acid—PLA2G4A—Integrated Pancreatic Cancer Pathway—TP53—amyotrophic lateral sclerosis	4.71e-05	0.000532	CbGpPWpGaD
Niflumic Acid—PLA2G4A—Signaling Pathways—GFAP—amyotrophic lateral sclerosis	4.47e-05	0.000505	CbGpPWpGaD
Niflumic Acid—PTGS2—Disease—PLB1—amyotrophic lateral sclerosis	4.47e-05	0.000505	CbGpPWpGaD
Niflumic Acid—PLA2G4A—Signaling Pathways—C5AR1—amyotrophic lateral sclerosis	4.42e-05	0.0005	CbGpPWpGaD
Niflumic Acid—UGT1A9—Metabolism—CHAT—amyotrophic lateral sclerosis	4.38e-05	0.000495	CbGpPWpGaD
Niflumic Acid—PLA2G4A—Hemostasis—IGF1—amyotrophic lateral sclerosis	4.38e-05	0.000495	CbGpPWpGaD
Niflumic Acid—PTGS1—Metabolism—GSR—amyotrophic lateral sclerosis	4.35e-05	0.000491	CbGpPWpGaD
Niflumic Acid—UGT1A9—Metabolism of lipids and lipoproteins—APOE—amyotrophic lateral sclerosis	4e-05	0.000452	CbGpPWpGaD
Niflumic Acid—PTGS2—Disease—VCP—amyotrophic lateral sclerosis	3.98e-05	0.00045	CbGpPWpGaD
Niflumic Acid—PTGS1—Metabolism of lipids and lipoproteins—PLA2G4A—amyotrophic lateral sclerosis	3.96e-05	0.000448	CbGpPWpGaD
Niflumic Acid—PTGS2—Integrated Pancreatic Cancer Pathway—CASP3—amyotrophic lateral sclerosis	3.94e-05	0.000445	CbGpPWpGaD
Niflumic Acid—PTGS2—Metabolism—PLB1—amyotrophic lateral sclerosis	3.74e-05	0.000423	CbGpPWpGaD
Niflumic Acid—PTGS2—Spinal Cord Injury—TP53—amyotrophic lateral sclerosis	3.71e-05	0.00042	CbGpPWpGaD
Niflumic Acid—SLC16A1—Hemostasis—VEGFA—amyotrophic lateral sclerosis	3.68e-05	0.000416	CbGpPWpGaD
Niflumic Acid—SLC16A1—Metabolism—GSTP1—amyotrophic lateral sclerosis	3.65e-05	0.000413	CbGpPWpGaD
Niflumic Acid—PTGS1—Metabolism—CHAT—amyotrophic lateral sclerosis	3.57e-05	0.000404	CbGpPWpGaD
Niflumic Acid—PTGS2—Metabolism—GSR—amyotrophic lateral sclerosis	3.45e-05	0.00039	CbGpPWpGaD
Niflumic Acid—SLC16A1—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	3.36e-05	0.000379	CbGpPWpGaD
Niflumic Acid—PTGS2—Integrated Pancreatic Cancer Pathway—VEGFA—amyotrophic lateral sclerosis	3.34e-05	0.000378	CbGpPWpGaD
Niflumic Acid—PLA2G4A—Metabolism of lipids and lipoproteins—PTGS2—amyotrophic lateral sclerosis	3.31e-05	0.000374	CbGpPWpGaD
Niflumic Acid—PLA2G4A—Signaling by GPCR—C3—amyotrophic lateral sclerosis	3.27e-05	0.000369	CbGpPWpGaD
Niflumic Acid—PTGS1—Metabolism of lipids and lipoproteins—APOE—amyotrophic lateral sclerosis	3.26e-05	0.000368	CbGpPWpGaD
Niflumic Acid—PLA2G1B—Metabolism—PTGS2—amyotrophic lateral sclerosis	3.24e-05	0.000366	CbGpPWpGaD
Niflumic Acid—PTGS2—Metabolism of lipids and lipoproteins—PLA2G4A—amyotrophic lateral sclerosis	3.14e-05	0.000355	CbGpPWpGaD
Niflumic Acid—PLA2G4A—Signaling Pathways—SQSTM1—amyotrophic lateral sclerosis	3.04e-05	0.000343	CbGpPWpGaD
Niflumic Acid—PLA2G4A—Hemostasis—VEGFA—amyotrophic lateral sclerosis	2.86e-05	0.000323	CbGpPWpGaD
Niflumic Acid—PTGS2—Disease—CST3—amyotrophic lateral sclerosis	2.86e-05	0.000323	CbGpPWpGaD
Niflumic Acid—PLA2G4A—Signaling Pathways—ATF1—amyotrophic lateral sclerosis	2.85e-05	0.000322	CbGpPWpGaD
Niflumic Acid—PLA2G4A—Metabolism—GSTP1—amyotrophic lateral sclerosis	2.84e-05	0.000321	CbGpPWpGaD
Niflumic Acid—PTGS2—Metabolism—CHAT—amyotrophic lateral sclerosis	2.84e-05	0.00032	CbGpPWpGaD
Niflumic Acid—SLC16A1—Hemostasis—TP53—amyotrophic lateral sclerosis	2.78e-05	0.000314	CbGpPWpGaD
Niflumic Acid—SLC16A1—Metabolism—APOE—amyotrophic lateral sclerosis	2.76e-05	0.000312	CbGpPWpGaD
Niflumic Acid—UGT1A9—Metabolism of lipids and lipoproteins—PTGS2—amyotrophic lateral sclerosis	2.74e-05	0.000309	CbGpPWpGaD
Niflumic Acid—PLA2G4A—Signaling Pathways—CASP9—amyotrophic lateral sclerosis	2.71e-05	0.000307	CbGpPWpGaD
Niflumic Acid—PTGS2—Metabolism of lipids and lipoproteins—APOE—amyotrophic lateral sclerosis	2.59e-05	0.000292	CbGpPWpGaD
Niflumic Acid—PTGS2—Integrated Pancreatic Cancer Pathway—TP53—amyotrophic lateral sclerosis	2.53e-05	0.000285	CbGpPWpGaD
Niflumic Acid—UGT1A9—Metabolism—GSTP1—amyotrophic lateral sclerosis	2.36e-05	0.000266	CbGpPWpGaD
Niflumic Acid—PLA2G4A—Signaling Pathways—ERBB4—amyotrophic lateral sclerosis	2.32e-05	0.000262	CbGpPWpGaD
Niflumic Acid—PTGS1—Metabolism of lipids and lipoproteins—PTGS2—amyotrophic lateral sclerosis	2.23e-05	0.000252	CbGpPWpGaD
Niflumic Acid—UGT1A9—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	2.16e-05	0.000244	CbGpPWpGaD
Niflumic Acid—PLA2G4A—Hemostasis—TP53—amyotrophic lateral sclerosis	2.16e-05	0.000244	CbGpPWpGaD
Niflumic Acid—PLA2G4A—Metabolism—APOE—amyotrophic lateral sclerosis	2.15e-05	0.000243	CbGpPWpGaD
Niflumic Acid—PTGS2—Disease—CASP9—amyotrophic lateral sclerosis	2.08e-05	0.000235	CbGpPWpGaD
Niflumic Acid—PLA2G4A—Signaling Pathways—C3—amyotrophic lateral sclerosis	1.93e-05	0.000218	CbGpPWpGaD
Niflumic Acid—PTGS1—Metabolism—GSTP1—amyotrophic lateral sclerosis	1.92e-05	0.000217	CbGpPWpGaD
Niflumic Acid—SLC16A1—Metabolism—PTGS2—amyotrophic lateral sclerosis	1.89e-05	0.000214	CbGpPWpGaD
Niflumic Acid—PLA2G4A—Signaling Pathways—APOE—amyotrophic lateral sclerosis	1.8e-05	0.000203	CbGpPWpGaD
Niflumic Acid—UGT1A9—Metabolism—APOE—amyotrophic lateral sclerosis	1.78e-05	0.000201	CbGpPWpGaD
Niflumic Acid—PTGS2—Disease—ERBB4—amyotrophic lateral sclerosis	1.78e-05	0.000201	CbGpPWpGaD
Niflumic Acid—PTGS1—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	1.76e-05	0.000199	CbGpPWpGaD
Niflumic Acid—PTGS2—Metabolism—GSTP1—amyotrophic lateral sclerosis	1.52e-05	0.000172	CbGpPWpGaD
Niflumic Acid—PLA2G4A—Signaling Pathways—IGF1—amyotrophic lateral sclerosis	1.48e-05	0.000168	CbGpPWpGaD
Niflumic Acid—PLA2G4A—Metabolism—PTGS2—amyotrophic lateral sclerosis	1.47e-05	0.000166	CbGpPWpGaD
Niflumic Acid—PTGS1—Metabolism—APOE—amyotrophic lateral sclerosis	1.45e-05	0.000164	CbGpPWpGaD
Niflumic Acid—PTGS2—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	1.4e-05	0.000158	CbGpPWpGaD
Niflumic Acid—PTGS2—Disease—APOE—amyotrophic lateral sclerosis	1.38e-05	0.000155	CbGpPWpGaD
Niflumic Acid—UGT1A9—Metabolism—PTGS2—amyotrophic lateral sclerosis	1.22e-05	0.000138	CbGpPWpGaD
Niflumic Acid—PTGS2—Metabolism—APOE—amyotrophic lateral sclerosis	1.15e-05	0.00013	CbGpPWpGaD
Niflumic Acid—PLA2G4A—Signaling Pathways—CASP3—amyotrophic lateral sclerosis	1.14e-05	0.000129	CbGpPWpGaD
Niflumic Acid—PLA2G4A—Signaling Pathways—MMP9—amyotrophic lateral sclerosis	1.08e-05	0.000122	CbGpPWpGaD
Niflumic Acid—PTGS1—Metabolism—PTGS2—amyotrophic lateral sclerosis	9.95e-06	0.000112	CbGpPWpGaD
Niflumic Acid—PLA2G4A—Signaling Pathways—VEGFA—amyotrophic lateral sclerosis	9.7e-06	0.00011	CbGpPWpGaD
Niflumic Acid—PLA2G4A—Signaling Pathways—TP53—amyotrophic lateral sclerosis	7.33e-06	8.28e-05	CbGpPWpGaD
